By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Allergan Inc. 

2525 Dupont Drive

Irvine  California  92612  U.S.A.
Phone: 714-246-4500 Fax: n/a


SEARCH JOBS

Allergan is a multi-specialty health care company established more than 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life’s potential. Today, we have approximately 11,100 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics, medical devices and over-the-counter consumer products, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. For the year ending 2012, our total product net sales totaled $5.5 billion, a 10 percent increase over 2011. From our beginnings as an eye care company to our focus today on several medical specialties, including eye care, neurosciences, medical aesthetics, medical dermatology, breast aesthetics, obesity intervention and urologics, Allergan is proud to celebrate more than six decades of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. For more information regarding Allergan, go to: www.allergan.com.


Key Statistics


Email: Corpinfo@allergan.com
Ownership: Public

Web Site: Allergan
Employees: 11,100
Symbol: AGN
 



Industry
Pharmaceutical


Collaborations

Elan Pharmaceuticals 

CeNes Pharmaceuticals (U.S.) 

PanVera LLC 

Pharmagene Laboratories Limited  Phase ZERO(TM) products and services.

Acadia  Discovery of alpha adrenergic drug candidates that may represent a significant breakthrough in the treatment of neuropathic pain.

Acadia  Develop and commercialize selective muscarinic drugs for the treatment of glaucoma.

Acadia  The third collaboration is designed to leverage ACADIA's R&D platform to discover and develop new therapeutics predominantly in the area of pain.





Company News
On Heels of Pfizer (PFE) Deal, Allergan (AGN) Eyes Texas Plant for Huge Investment, Possible Jobs 2/1/2016 2:36:35 PM
Allergan (AGN) Announces Collaboration With AstraZeneca PLC (AZN) To Develop And Commercialize ATM-AVI (aztreonam And avibactam) For Antibiotic-Resistant Gram-Negative Infections 1/29/2016 6:20:34 AM
Independent Baylor University Study Showcases Economic Impact Of Allergan (AGN) On Waco And Central Texas Economies 1/29/2016 6:10:27 AM
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression 1/29/2016 5:49:56 AM
Allergan (AGN) Release: U.S. FDA Approves BOTOX (onabotulinumtoxinA) For The Treatment Of Lower Limb Spasticity In Adults 1/22/2016 6:28:13 AM
Allergan (AGN) Release: VIBERZI (eluxadoline) Phase III Trial Results Published In The New England Journal of Medicine 1/21/2016 5:59:16 AM
Allergan (AGN) Announces FDA Approval Of Updated Label For New Dosing Regimen For DALVANCE (dalbavancin) 1/21/2016 5:57:33 AM
Allergan (AGN) To Report Fourth Quarter And Full-Year 2015 Earnings And Host Conference Call And Webcast 1/20/2016 6:41:37 AM
Where Pfizer (PFE)-Allergan (AGN) May Be 10 Years Down the Road 1/19/2016 6:35:32 AM
Allergan (AGN) Release: Rapastinel (GLYX-13) Shown To Improve Ketamine Or PCP-Induced Cognitive Impairment In Mice 1/19/2016 6:21:29 AM
12345678910...
//-->